利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

95 条记录 (耗时 0.027 秒)

    MODIFIED T CELL RECEPTORS AND RELATED MATERIALS AND METHODS
    3.
    发明申请
    MODIFIED T CELL RECEPTORS AND RELATED MATERIALS AND METHODS 有权
    改良的T细胞受体及相关材料与方法

    公开(公告)号：US20120071420A1

    公开(公告)日：2012-03-22

    申请号：US13304841

    申请日：2011-11-28

    申请人： Paul F. Robbins ,  Richard A. Morgan ,  Steven A. Rosenberg ,  Alan David Bennett

    发明人： Paul F. Robbins ,  Richard A. Morgan ,  Steven A. Rosenberg ,  Alan David Bennett

    IPC分类号： A61K38/02 ,  A61P31/00 ,  C12Q1/02 ,  A61P35/00

    CPC分类号： G01N33/505 ,  A61K38/00 ,  C07K14/7051 ,  G01N33/5091

    摘要： The invention is directed to a modified T cell receptor (TCR) comprising an amino acid sequence of a wild-type (WT) TCR with no more than three amino acid substitutions, wherein the modified TCR, as compared to the WT TCR, (i) has an enhanced ability to recognize target cells when expressed by CD4+ T cells and (ii) does not exhibit a decrease in antigen specificity when expressed by CD8+ T cells. Polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, and pharmaceutical compositions related to the modified TCR also are part of the invention. Further, the invention is directed to methods of detecting a diseased cell in a host, methods of treating or preventing a disease in a host, and methods of identifying a candidate adoptive immunotherapy TCR.

    摘要翻译： 本发明涉及包含不超过三个氨基酸取代的野生型（WT）TCR的氨基酸序列的修饰的T细胞受体（TCR），其中与WT TCR相比，修饰的TCR（i ）当由CD4 + T细胞表达时具有增强的识别靶细胞的能力，和（ii）当由CD8 + T细胞表达时不显示抗原特异性的降低。 多肽，蛋白质，核酸，重组表达载体，宿主细胞，细胞群，抗体和与修饰的TCR相关的药物组合物也是本发明的一部分。 此外，本发明涉及检测宿主中的病变细胞的方法，治疗或预防宿主疾病的方法，以及鉴定候选的过继性免疫治疗TCR的方法。

    MODIFIED T CELL RECEPTORS AND RELATED MATERIALS AND METHODS
    4.
    发明申请
    MODIFIED T CELL RECEPTORS AND RELATED MATERIALS AND METHODS 有权
    改良的T细胞受体及相关材料与方法

    公开(公告)号：US20100034834A1

    公开(公告)日：2010-02-11

    申请号：US12443111

    申请日：2007-09-26

    申请人： Paul F. Robbins ,  Richard A. Morgan ,  Steven A. Rosenberg ,  Alan David Bennett

    发明人： Paul F. Robbins ,  Richard A. Morgan ,  Steven A. Rosenberg ,  Alan David Bennett

    IPC分类号： A61K39/395 ,  C07K16/30 ,  C12N15/11 ,  C12N15/00 ,  C12N5/10 ,  G01N33/53 ,  G01N33/574 ,  C12Q1/68

    CPC分类号： G01N33/505 ,  A61K38/00 ,  C07K14/7051 ,  G01N33/5091

    摘要： The invention is directed to a modified T cell receptor (TCR) comprising an amino acid sequence of a wild-type (WT) TCR with no more than three amino acid substitutions, wherein the modified TCR, as compared to the WT TCR, (i) has an enhanced ability to recognize target cells when expressed by CD4+ T cells and (ii) does not exhibit a decrease in antigen specificity when expressed by CD8+ T cells. Polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, and pharmaceutical compositions related to the modified TCR also are part of the invention. Further, the invention is directed to methods of detecting a diseased cell in a host, methods of treating or preventing a disease in a host, and methods of identifying a candidate adoptive immunotherapy TCR.

    摘要翻译： 本发明涉及包含不超过三个氨基酸取代的野生型（WT）TCR的氨基酸序列的修饰的T细胞受体（TCR），其中与WT TCR相比，修饰的TCR（i ）当由CD4 + T细胞表达时具有增强的识别靶细胞的能力，和（ii）当由CD8 + T细胞表达时不显示抗原特异性的降低。 多肽，蛋白质，核酸，重组表达载体，宿主细胞，细胞群，抗体和与修饰的TCR相关的药物组合物也是本发明的一部分。 此外，本发明涉及检测宿主中的病变细胞的方法，治疗或预防宿主疾病的方法，以及鉴定候选的过继性免疫治疗TCR的方法。

    Modified T cell receptors and related materials and methods
    5.
    发明授权
    Modified T cell receptors and related materials and methods 有权
    改良T细胞受体及相关材料及方法

    公开(公告)号：US09128080B2

    公开(公告)日：2015-09-08

    申请号：US13304841

    申请日：2011-11-28

    申请人： Paul F. Robbins ,  Richard A. Morgan ,  Steven A. Rosenberg

    发明人： Paul F. Robbins ,  Richard A. Morgan ,  Steven A. Rosenberg

    IPC分类号： C07H21/04 ,  G01N33/50 ,  C07K14/725 ,  A61K38/00

    CPC分类号： G01N33/505 ,  A61K38/00 ,  C07K14/7051 ,  G01N33/5091

    摘要： The invention is directed to a modified T cell receptor (TCR) comprising an amino acid sequence of a wild-type (WT) TCR with no more than three amino acid substitutions, wherein the modified TCR, as compared to the WT TCR, (i) has an enhanced ability to recognize target cells when expressed by CD4+ T cells and (ii) does not exhibit a decrease in antigen specificity when expressed by CD8+ T cells. Polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, and pharmaceutical compositions related to the modified TCR also are part of the invention. Further, the invention is directed to methods of detecting a diseased cell in a host, methods of treating or preventing a disease in a host, and methods of identifying a candidate adoptive immunotherapy TCR.

    摘要翻译： 本发明涉及包含不超过三个氨基酸取代的野生型（WT）TCR的氨基酸序列的修饰的T细胞受体（TCR），其中与WT TCR相比，修饰的TCR（i ）当由CD4 + T细胞表达时具有增强的识别靶细胞的能力，和（ii）当由CD8 + T细胞表达时不显示抗原特异性的降低。 多肽，蛋白质，核酸，重组表达载体，宿主细胞，细胞群，抗体和与修饰的TCR相关的药物组合物也是本发明的一部分。 此外，本发明涉及检测宿主中的病变细胞的方法，治疗或预防宿主疾病的方法，以及鉴定候选的过继性免疫治疗TCR的方法。

    MODIFIED T CELL RECEPTORS AND RELATED MATERIALS AND METHODS
    7.
    发明申请
    MODIFIED T CELL RECEPTORS AND RELATED MATERIALS AND METHODS 审中-公开
    改良的T细胞受体及相关材料与方法

    公开(公告)号：US20100297093A1

    公开(公告)日：2010-11-25

    申请号：US12679526

    申请日：2008-09-23

    申请人： Paul F. Robbins ,  Steven A. Rosenberg ,  Richard A. Morgan

    发明人： Paul F. Robbins ,  Steven A. Rosenberg ,  Richard A. Morgan

    IPC分类号： A61K35/26 ,  G01N33/53 ,  C12N5/10 ,  C07K14/00 ,  C07H21/04 ,  A61P35/00

    CPC分类号： C07K14/705

    摘要： The invention is directed to a modified T cell receptor (TCR) comprising an amino acid sequence of a wild-type (WT) TCR with one or more amino acid substitutions in the CDR2 and/or CDR3 regions of the alpha and/or beta chains of the TCR, wherein the modified TCR, as compared to the WT TCR, (i) has an enhanced ability to recognize target cells when expressed by CD4+ T cells and/or CD8+ T cells and (ii) does not exhibit a decrease in antigen specificity when expressed by the CD4+ T cells and/or CD8+ T cells. Polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, and pharmaceutical compositions related to the modified TCR also are part of the invention. Further, the invention is directed to methods of treating or preventing a disease in a host and methods of detecting a diseased cell in a host.

    摘要翻译： 本发明涉及一种修饰的T细胞受体（TCR），其包含在α和/或β链的CDR2和/或CDR3区域中具有一个或多个氨基酸取代的野生型（WT）TCR的氨基酸序列 的TCR，其中与WT TCR相比，修饰的TCR，（i）当由CD4 + T细胞和/或CD8 + T细胞表达时具有增强的识别靶细胞的能力，和（ii）不显示抗原的降低 当由CD4 + T细胞和/或CD8 + T细胞表达时的特异性。 多肽，蛋白质，核酸，重组表达载体，宿主细胞，细胞群，抗体和与修饰的TCR相关的药物组合物也是本发明的一部分。 此外，本发明涉及治疗或预防宿主疾病的方法以及检测宿主中病变细胞的方法。

    Modified T cell receptors and related materials and methods
    9.
    发明授权
    Modified T cell receptors and related materials and methods 有权
    改良T细胞受体及相关材料及方法

    公开(公告)号：US08088379B2

    公开(公告)日：2012-01-03

    申请号：US12443111

    申请日：2007-09-26

    申请人： Paul F. Robbins ,  Richard A. Morgan ,  Steven A. Rosenberg ,  Alan David Bennett

    发明人： Paul F. Robbins ,  Richard A. Morgan ,  Steven A. Rosenberg ,  Alan David Bennett

    IPC分类号： A61K39/00 ,  G01N33/53 ,  G01N33/574 ,  C07K16/00 ,  C12P21/08

    CPC分类号： G01N33/505 ,  A61K38/00 ,  C07K14/7051 ,  G01N33/5091

    摘要： The invention is directed to a modified T cell receptor (TCR) comprising an amino acid sequence of a wild-type (WT) TCR with no more than three amino acid substitutions, wherein the modified TCR, as compared to the WT TCR, (i) has an enhanced ability to recognize target cells when expressed by CD4+ T cells and (ii) does not exhibit a decrease in antigen specificity when expressed by CD8+ T cells. Polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, and pharmaceutical compositions related to the modified TCR also are part of the invention. Further, the invention is directed to methods of detecting a diseased cell in a host, methods of treating or preventing a disease in a host, and methods of identifying a candidate adoptive immunotherapy TCR.

    摘要翻译： 本发明涉及包含不超过三个氨基酸取代的野生型（WT）TCR的氨基酸序列的修饰的T细胞受体（TCR），其中与WT TCR相比，修饰的TCR（i ）当由CD4 + T细胞表达时具有增强的识别靶细胞的能力，和（ii）当由CD8 + T细胞表达时不显示抗原特异性的降低。 多肽，蛋白质，核酸，重组表达载体，宿主细胞，细胞群，抗体和与修饰的TCR相关的药物组合物也是本发明的一部分。 此外，本发明涉及检测宿主中的病变细胞的方法，治疗或预防宿主疾病的方法，以及鉴定候选的过继性免疫治疗TCR的方法。

    MHC-class II restricted melanoma antigens and their use in therapeutic methods
    10.
    发明授权
    MHC-class II restricted melanoma antigens and their use in therapeutic methods 失效
    MHC-II类受限黑素瘤抗原及其在治疗方法中的应用

    公开(公告)号：US06951917B1

    公开(公告)日：2005-10-04

    申请号：US08533895

    申请日：1995-09-26

    申请人： Suzane L. Topalian ,  Steven A. Rosenberg ,  Paul F. Robbins

    发明人： Suzane L. Topalian ,  Steven A. Rosenberg ,  Paul F. Robbins

    IPC分类号： A61K38/00 ,  C07K14/74 ,  C12N9/02 ,  C07K7/00 ,  A01N63/00 ,  A61K39/00 ,  A61K39/385 ,  C07K14/705

    CPC分类号： C12N9/0059 ,  A61K38/00 ,  C07K14/70539

    摘要： The present invention provides MHC Class II restricted melanoma antigens recognized by CD4+ T cells. This invention further provides prophylactic and therapeutic applications for the Class II restricted melanoma antigens. In particular, this invention provides tyrosinase Class II restricted melanoma antigens, as well as tyrosinase immunogenic peptides which have been modified to enhance their immunogenicity. These antigens can serve as an immunogens or vaccines to prevent or treat melanoma. In addition a method for isolating Class II restricted melanoma antigens or identifying new Class II restricted melanoma antigens is provided.

    摘要翻译： 本发明提供由CD4 + T细胞识别的MHC II类限制性黑素瘤抗原。 本发明进一步提供II类受限黑素瘤抗原的预防和治疗应用。 特别地，本发明提供了酪氨酸酶II类受限制的黑素瘤抗原，以及已被修饰以增强其免疫原性的酪氨酸酶免疫原性肽。 这些抗原可以作为免疫原或疫苗来预防或治疗黑素瘤。 另外还提​​供了分离II类受限制的黑素瘤抗原或鉴定新的II类受限黑素瘤抗原的方法。